![moca cognitive assessment factsheet moca cognitive assessment factsheet](https://i1.rgstatic.net/publication/221732676_Montreal_Cognitive_Assessment_in_Detecting_Cognitive_Impairment_in_Chinese_Elderly_Individuals_A_Population-Based_Study/links/57563ce308ae155a87b9d11c/largepreview.png)
4-6 Digital assessments may reduce time and cost associated with cognitive testing. Integrating digital technologies into clinical practice and research has several possible benefits. We conclude with practical strategies for bringing digital devices into clinical workflows. 2,3 Passive digital phenotyping and virtual reality assessments are not covered here. Personal computer (PC)-based evaluations have been reviewed elsewhere. We then review advances in tablet- and smartphone-based digital assessments. We discuss benefits and limitations of adopting digital assessment tools and considerations for deciding which to use. In this review, we cover several topics we hope will guide clinical neurologists considering adoption of technology in their practice, with a focus on ADRD assessment. Digital technologies are well positioned for a role in remote evaluation. The necessity of validated remote evaluations is apparent, underscored by the recent limitations on in-person visits secondary to the COVID-19 pandemic. Paper-and-pencil tests have typically been administered face-to-face in the clinic. It is becoming clear, however, that there are myriad benefits to incorporating digital technologies into assessment. 1 Since the advent of clinical neuropsychologic assessments, these evaluations have been conducted using paper-and-pencil measures. 1 Cognitive assessment is an important part of ADRD diagnosis, and as we move into an age of ADRD therapeutics, accurate syndromic classification and disease monitoring will be a critical component of identifying trial participants and managing these diseases. 1 Early and accurate diagnosis of these conditions can mitigate costs and improve medical care and quality of life. Alzheimer disease and related dementias (ADRDs) are a global medical and public health challenge.